Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1463 | Hemanext One Wiki | 0.71 |
| drug322 | Association of diltiazem and niclosamide Wiki | 0.71 |
| drug3233 | Standard of care (SOC) Wiki | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.
Description: To assess the infusional toxicity
Measure: To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia Time: Day 28Description: To assess the number of Adverse events of special interest : Incidence of infections (bacterial, viral, fungal, parasitic) and thrombo-embolic events.
Measure: To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia Time: Day 28Description: Group A (patients not under mechanical ventilation): to determine the pourcentage of patients requiring mechanical ventilation
Measure: To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia Time: Day 28Description: Group B (patients under mechanical ventilation): to determine the vital status (dead/alive)
Measure: To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia Time: Day 28Description: To assess the clinical status (on a 7-point WHO ordinal scale)
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 28Description: To assess the duration of oxygen therapy and/or mechanical ventilation
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 28Description: To assess the length of stay at the intensive care unit and of hospitalization
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 90Description: To assess the number of organ failures
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 28Description: To assess the intensity of the inflammatory response
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 28Description: To assess the evolution of coagulation parameter
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 28Description: To assess the presence of Biomarker of lung lesion, repair and scarring
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 28Description: To assess the v iral load over the 28 days after inclusion and seroconversion to COVID-19 over the 90 days after inclusion
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 90Description: To assess the pulmonary function
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 90Description: To assess the number of adverse reactions (ARs), ARs grade > 3, serious adverse events (SAEs), serious ARs (SARs), suspected expected and unexpected SARs (SESARs and SUSARs).
Measure: To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy) Time: Day 90Description: To determine the FACS analysis of regulatory T-cell (Treg) levels and Treg and Tconv sub-populations
Measure: To investigate immune modulation Time: Day 28Description: To assess the cytotoxic activity by MLR
Measure: To compare the cytotoxic activity of PBMCs from healthy control and COVID-19 patients (divided in responders / non-responders to MSC therapy) against MSCs in vitro Time: Day 28This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2 associated Acute Respiratory Distress Syndrome (ARDS). After informed consent, treatment assignment will be made by computer-generated randomization to administer either MSC or vehicle placebo control with a 2:1 allocation to the MSC: placebo arm.
Description: Acute Lung Injury Score is a composite 4 point scoring system validated by the NHLBI ARDS Network that considers PaO2/FiO2, the level of positive end-expiratory airway pressure, respiratory compliance, and the extent of pulmonary infiltrates on the chest radiograph
Measure: Change in acute lung injury (ALI) score 2 Time: Baseline and Day 28 after first infusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports